25+ Long COVID Phenotyping List
- 4 days ago
- 6 min read
Clinical and Social Terrain Subtypes in Long COVID
Executive Summary
For years, Long COVID (Post-Acute Sequelae of SARS-CoV-2, PASC) has been treated as a single condition in research and clinical care, despite clear evidence of biological heterogeneity, multi-system involvement, and variable disease trajectories. This lack of stratification has contributed to clinical trial failure, inconsistent treatment outcomes, and widespread underdiagnosis (Institute of Medicine, 2015; Komaroff, 2021).
The CYNAERA 25+ Long COVID Phenotyping List integrates biological, environmental, and social terrain factors into a structured classification system. This framework aligns with CYNAERA’s broader modeling approaches, including VitalGuard™, and Antiviral Pairing Logic which identify patterns of instability across Long COVID.
This list is designed to support:
Adaptive clinical trial design for Long COVID subtypes
Personalized, phenotype-based care pathways
More accurate modeling of underdiagnosed and structurally overlooked populations
Core Domains of Phenotyping
Long COVID behaves less like a single condition and more like a system under strain, where multiple biological pathways shift together based on timing, triggers, and baseline stability. What patients experience is not just a list of symptoms, but a pattern. CYNAERA’s core phenotype domains capture those patterns by organizing Long COVID into interacting systems that shape how the condition presents, progresses, and responds to intervention.
Formula: Phenotype = Core Axis × Trigger/Modulator + Functional Signature
1. Energy, Exertion & Recovery Axis
PEM-Dominant Long COVID – exertion leads to delayed, multi-system symptom crash.
Cognitive PEM Variant – mental exertion triggers relapse.
Delayed-Onset PEM – flare occurs 24–72 hours after activity.
Remission-Relapse Oscillator – alternating stable and crash states.
Adrenergic Compensation Subtype – temporary function through stress-hormone overdrive, then collapse.
2. Autonomic & Circulatory Axis
POTS-Dominant Long COVID – tachycardia, orthostatic intolerance, palpitations.
Orthostatic Intolerance (Non-Tachycardic) – dizziness and fatigue without major HR spike.
Blood Volume/Perfusion Variant – low plasma volume, poor circulation, cognitive slowing.
Baroreflex Dysregulation – unstable blood pressure with positional stress.
Air Hunger / Post-Exertional Dyspnea Variant – breathlessness linked to autonomic or exertional instability.
3. Neurocognitive & Neuroinflammatory Axis
Neuroinflammatory Brain Fog – slowed processing, memory disruption, executive dysfunction.
Sensory Overload Dominant – hypersensitivity to light, sound, smell, or motion.
Cognitive-Motor Coordination Decline – impaired thinking and movement integration.
Visual-Spatial Processing Deficit – delayed motion or spatial awareness.
Neuroinflammatory Head Pressure – migraine-like symptoms and cognitive crashes.
4. Immune Activation, Viral Persistence & Reactivation Axis
Viral Persistence-Suspected Long COVID – ongoing antigen or viral reservoir activity.
Viral Reactivation Subtype – EBV, HHV-6, HSV, or similar reactivation linked to flares.
Immune Fragility Variant – recurrent infections or poor immune recovery.
Mast Cell Activation Overlap – histamine intolerance, flushing, airway reactivity, allergic-type symptoms.
Steroid-Responsive or Steroid-Destabilized Pattern – variable response to immune suppression.
5. Cardiovascular & Chest Symptom Axis
Palpitation-Dominant Long COVID – irregular heartbeat, tachycardia, adrenaline surges.
Chest Pain / Pressure Subtype – inflammatory, vascular, or musculoskeletal chest discomfort.
Exertional Cardiac Intolerance – activity triggers disproportionate symptom escalation.
Residual Cardio-Pulmonary Injury Variant – lingering symptoms after cardiac or lung involvement.
6. Gastrointestinal, Metabolic & Nutritional Axis
GI Dysmotility – nausea, bloating, constipation, diarrhea, or gastroparesis-like symptoms.
Food Reactivity Subtype – symptom worsening with specific foods or histamine load.
Malabsorption / Nutrient Depletion Variant – deficiencies worsening illness severity.
Metabolic Instability – blood sugar dysregulation and energy crashes.
7. Hormonal & Endocrine Axis
Cycle-Triggered Long COVID – symptom flares linked to menstrual cycle.
Estrogen Withdrawal Subtype – worsening during perimenopause or menopause.
Postpartum Long COVID – onset or worsening after childbirth.
Hormone-Sensitive Variant – symptom shifts with endocrine changes or therapy.
8. Sleep, Pain & Neurological Excitability Axis
Non-Restorative Sleep – unrefreshing sleep despite adequate duration.
Circadian Rhythm Disruption – delayed or reversed sleep-wake cycle.
Pain-Dominant Long COVID – neuropathic pain, headaches, muscle pain, body pressure.
Neuro-Excitability Subtype – tremors, internal vibrations, startle, or sensory overactivation.
9. Functional Severity & Disease Progression Axis
Mild but Unstable Long COVID – outward function with frequent relapses.
Housebound Intermittent – mobility preserved only through strict pacing.
Severe / Bedbound Subtype – profound disability with major sensory and functional limitation.
Multi-System Progression Variant – accumulation of new symptoms over time.
Partial Remission but Fragile – improved baseline with high relapse risk.
10. Social, Structural & Access-Constrained Modifiers
These do not define biological phenotype alone but strongly shape severity, diagnosis, and progression:
BIPOC Misdiagnosed Variant – symptoms dismissed, fragmented, or misclassified.
Women Misdiagnosed as Anxiety – autonomic, immune, or endocrine symptoms minimized.
Men Misdiagnosed as Burnout – underrecognized due to cultural and diagnostic assumptions.
Pediatric Misattribution – symptoms mislabeled as behavioral, developmental, or psychological.
Low-Income Access Barrier – delayed diagnosis and limited access to care.
Mold / Environmental Exposure Overlay – smoke, mold, housing, or chemical triggers worsen symptoms.
Food Insecurity Overlay – nutritional instability amplifies flares and recovery difficulty.
Caregiver Constraint Overlay – inability to rest or pace due to family responsibilities.
Medical Gaslighting Overlay – delayed care and progression shaped by repeated dismissal.
Why This Matters
Clinical Trials:
Stratifying Long COVID into clinically meaningful subtypes improves signal detection and supports targeted therapeutic development, particularly for interventions tied to immune dysfunction, autonomic instability, viral persistence, and post-exertional symptom escalation. This classification logic aligns with CYNAERA’s Composite Diagnostic Fingerprint (CDF) for Long COVID, which emphasizes the importance of structured subgrouping for more accurate research and clinical interpretation.
Clinical Care:
Phenotype-based classification enables more precise care by identifying whether a patient’s dominant drivers are PEM, dysautonomia, immune activation, endocrine disruption, respiratory instability, or environmental exposure. This approach is consistent with Remission Pathways in Long COVID: Drug Combinations, Chronicity & Socio-Biologic Terrain, which argues that treatment response depends on timing, terrain, and patient-specific instability patterns.
Accuracy and System-Level Insight:
Long COVID outcomes are shaped not only by biology but by diagnostic timing, environmental conditions, pediatric underrecognition, sex-based and race-linked misclassification, and real-world access constraints. Incorporating these modifiers improves prevalence estimates, care pathways, and long-term forecasting. This broader view is reinforced by One New Long COVID Case Every Minute in the United States, which frames Long COVID as a continuing large-scale public health burden rather than a narrow post-viral niche.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID, ME/CFS and CRISPR Remission Libraries are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
Comments